N@N

Gilead Sciences Files Patent Infringement Lawsuit Against Lupin Limited

_{//health-fitness.news-articles.net/content/2010/ .. -infringement-lawsuit-against-lupin-limited.html}
^{Published in Health and Fitness on Wednesday, July 14th 2010 at 15:15 GMT by Market Wire}  

FOSTER CITY, Calif.--([ BUSINESS WIRE ])--Gilead Sciences, Inc. (Nasdaq:GILD) today announced that it has filed a lawsuit in U.S. District Court in New Jersey against Lupin Limited for infringement against Gileada™s patents for Ranexa^® (ranolazine extended-release tablets). The lawsuit is based on an Abbreviated New Drug Application filed by Lupin, which seeks approval to manufacture and market a generic version of Ranexa before the expiration of Gileada™s Ranexa patents.

Ranexa is currently protected by 10 patents, which are listed in the FDAa™s Approved Drug Products List, and all 10 patents would need to be invalidated, expire or not be infringed before a generic version of Ranexa could be marketed.

Gilead has full confidence in the validity of its patents and plans to vigorously defend the intellectual property rights of Ranexa.

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.

Forward-Looking Statement

This press release includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that are subject to risks, uncertainties and other factors, including uncertainty related to whether Gileada™s patent infringement lawsuit against Lupin will be successful. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead's Quarterly Report on Form 10-Q for the first quarter of 2010, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.

Ranexa is a registered trademark of Gilead Sciences, Inc.

For more information on Gilead, please call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235) or visit [ www.gilead.com ]